With the Pfizer (PFE)/BioNTech (BNTX) booster guidance in the rearview mirror, the CDC and the country’s other regulatory and public health agencies are gearing up to tackle Moderna’s (MRNA) and eventually Johnson & Johnson’s (JNJ) booster filings for recipients of those vaccines.
Meanwhile, many have wondered why the U.S. is not following Europe’s and Canada’s lead in allowing mixing and matching of vaccine brands in order to be considered fully vaccinated or for booster doses.
CDC Director Dr. Rochelle Walensky told that information is not too far away.
“We’re starting to see some of the mix-and-match data,” she said, noting that studies are already underway.
“As soon as we have those data to present, both to the FDA and to the CDC, we’ll have recommendations there as well,” Walensky said.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), said Tuesday the first batch of data pertains to Moderna as a booster for either the J&J or Pfizer vaccines.
That data is available now, and data from trials of the other two vaccines as mixed boosters are forthcoming in the next month.
Source: Yahoo Finance
Antibiotic Prescriptions Associated With COVID-19 Outpatient Visits Among Medicare Beneficiaries, April 2020 to April 2021
Outpatient Visits for COVID-19 and Associated Antibiotic Prescriptions Among Medicare Beneficiaries Aged 65 Years or Older, by Setting, US, April 2020 to April 2021. The volume of COVID-19 visits differed by setting: emergency department, 525 608 (45.8% of all visits); office, 295 983 (25.3%); telehealth, 260 261 (22.3%); and urgent care, 77 268 (6.6%).
Source: Journal of American Medical Association Network